Strategic alliance for clinical research announced
Research Dynamics Consulting Group and ClinROC LLC have announced a strategic alliance to provide clinical research and product development services for the ophthalmic industry.
Research Dynamics Consulting Group and ClinROC LLC have announced a strategic alliance to provide clinical research and product development services for the ophthalmic industry.
ClinROC LLC will collaborate with Research Dynamics Consulting Group to offer clinical knowledge and experience in ophthalmology. The move will see cost-efficient conduct and management of clinical research trials for the ophthalmic, biologic and medical device industries.
Lorraine D. Ellis, CEO of the Research Consulting Group, commented, "Working with ClinROC provides our clients with our operational efficiency and ophthalmology trial experience together with ClinROC’s extensive medical and clinical expertise.” The strategic partnership with Research Dynamics Consulting Group is the latest exciting development for ClinROC, LLC and concentrates on meeting the development needs of ophthalmic medical devices, pharmaceuticals and diagnostics."
Dr Tara Vaz, Clinical Affairs and Co-Founder of ClinROC LLC, added, "This alliance allows our companies to conduct various designs and sizes of clinical trials to the highest quality standards, while providing the medical, clinical and scientific oversight to ensure the robustness of the outcomes."
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
